Chemours (NYSE:CC) PT Lowered to $30.00 at Barclays

Chemours (NYSE:CCGet Free Report) had its target price decreased by Barclays from $32.00 to $30.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the specialty chemicals company’s stock. Barclays‘s price target would indicate a potential upside of 9.21% from the company’s current price.

CC has been the subject of several other research reports. BMO Capital Markets downgraded shares of Chemours from an “outperform” rating to an “underperform” rating and reduced their price target for the company from $45.00 to $19.00 in a report on Thursday, February 29th. UBS Group reaffirmed a “neutral” rating and set a $21.00 price target (down previously from $37.00) on shares of Chemours in a report on Tuesday, March 5th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Chemours has an average rating of “Hold” and a consensus target price of $28.44.

Read Our Latest Research Report on CC

Chemours Stock Performance

Shares of NYSE CC traded down $1.27 during mid-day trading on Tuesday, hitting $27.47. The company had a trading volume of 1,335,188 shares, compared to its average volume of 2,039,726. The stock has a market cap of $4.09 billion, a price-to-earnings ratio of -17.74 and a beta of 2.00. The firm’s 50 day simple moving average is $27.94 and its two-hundred day simple moving average is $28.02. The company has a debt-to-equity ratio of 5.40, a current ratio of 1.54 and a quick ratio of 1.00. Chemours has a 12 month low of $15.10 and a 12 month high of $39.05.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Hexagon Capital Partners LLC bought a new position in Chemours during the 4th quarter valued at $25,000. Legacy Financial Group LLC bought a new position in Chemours during the third quarter valued at about $29,000. Garner Asset Management Corp bought a new position in Chemours during the fourth quarter valued at about $29,000. Morton Brown Family Wealth LLC acquired a new position in Chemours during the fourth quarter worth about $35,000. Finally, Neo Ivy Capital Management bought a new stake in Chemours in the fourth quarter worth about $40,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Company Profile

(Get Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Featured Stories

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.